Novo Nordisk: Tresiba shows positive post-hoc results
(CercleFinance.com) - People with both type-1 and type-2 diabetes may achieve improved glycaemic control with Novo Nordisk's Tresiba compared to Sanofi's insulin glargine U-100, i.
e. Lantus, without an increase in hypoglycaemia, according to results of a post-hoc analysis presented on Tuesday.
Novo today presented the results of two phase 3b trials today at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin.
The trials demonstrated statistically significantly lower rates of overall symptomatic hypoglycaemia versus insulin glargine U100 in people with type-1 and type-2 diabetes, the Danish company said.
Novo also said that people with type-2 diabetes achieved similar blood sugar control with half the number of daily injections with its once-daily pen Ryzodeg, compared to insulin glargine U100, significantly lowering total daily insulin dose.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
e. Lantus, without an increase in hypoglycaemia, according to results of a post-hoc analysis presented on Tuesday.
Novo today presented the results of two phase 3b trials today at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin.
The trials demonstrated statistically significantly lower rates of overall symptomatic hypoglycaemia versus insulin glargine U100 in people with type-1 and type-2 diabetes, the Danish company said.
Novo also said that people with type-2 diabetes achieved similar blood sugar control with half the number of daily injections with its once-daily pen Ryzodeg, compared to insulin glargine U100, significantly lowering total daily insulin dose.
Copyright (c) 2018 CercleFinance.com. All rights reserved.